Abstract
The economic reforms introduced in India in 1991 were a reversal of earlier policies which helped access to affordable medicines by the development of a strong generic pharmaceutical industry. Liberalisation of import restrictions, reduction of tariffs, removal of restrictions on foreign investment and introduction of product patents rights are all expected to have a profound impact on the industry. Cost of medicines being the most critical factor in the healthcare system in India, these reforms would have definite implications for the universal healthcare programme. This paper provides an analysis of the implications of reforms for the universal healthcare programme in the country.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ayyangar, J. N. R. (1959). Report on the Revision of the Patents Law, Ministry of Commerce and Industry.
Dey, S. (2008). Sick Bulk Drug Cos May Get Life Support. The Economic Times, August 15, 2008.
Ebrahim, Z. (2012). India poised to supply free drugs to 1.2 billion people. Inter Press Service News Agency, November 8, 2012.
Federation of Indian Chambers of Commerce and Industry (FICCI). (2005). Competitiveness of the Indian pharmaceutical industry in the new product patent regime [FICCI Report for National Manufacturing Competitiveness Council (NMCC)]. FICCI.
Ghosh, A., & Keayla, B. K. (1998). Report of people’s commission on intellectual property rights. National Working Group on Patent Laws.
Glaxo, Smith Kline plc. (GSK). (2009). GSK announces a strategic alliance with Dr. Reddy’s to further accelerate sales growth in emerging markets. June 15, 2009. Accessed September 22, 2011. http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10064.htm
Hamied, Y. K. (1988). The Indian Patents Act 1970 and the Pharmaceutical Industry. Conquest by Patent: On Patent Law and Policy. National Working Group on Patent Laws.
Government of India. (1975). Report of the committee on the drugs and pharmaceutical industry (April 1975). Ministry of Petroleum and Chemicals.
IBEF (India Brand Equity Foundation). (2011). Pharmaceuticals. Accessed October 30, 2014. http://ukrexport.gov.ua/i/imgsupload/file/Pharma_sectoral.pdf
Information and Credit Rating Agency (ICRA). (2011). CRAMS India: Overlook and outlook. Accessed January 20, 2016. http://www.icra.in/Files/Articles/CRAMS%20Note,%20Overview%20and%20Outlook.pdf
Joseph, R. K. (2016). Pharmaceutical industry and public policy in post-reform India. Routledge.
Keayla, B. K. (1994). Patent protection and pharmaceutical industry. In K. R. G. Nair, & A. Kumar (Eds.), Intellectual property rights. Allied Publishers.
Kumar, V. (2004). Committees and commissions in India Vol. 1: 1947–54. Concept Publishing Co.
Mahesh, K. (2006). 70 Pharma Firms Shut Shop. The Times of India, January 24, 2006.
Ministry of Commerce and Industry, Government of India. (2008). Strategy for increasing exports of pharmaceutical products. Ministry of Commerce and Industry.
Ministry of Industry and Supply, Government of India. (1948). Industrial policy statement. Ministry of Industry and Supply.
Ministry of Industry, Government of India. (1991). Statement on industrial policy. Ministry of Industry.
Ministry of Petroleum and Chemicals, Government of India. (1975). Report of the committee in drugs and pharmaceutical industry. Ministry of Petroleum and Chemicals.
Mumbai Bureau, PHARMABIZ.com. (2009). Empower SMEs while embracing GMP, November 5, 2009. Accessed February 27, 2018. http://saffron.pharmabiz.com/article/detnews.asp?articleid=52445§ionid=50
Narayana, P. L. (1984). The Indian pharmaceutical industry: Problems and prospects. National Council of Applied Economic Research.
NSSO (National Sample Survey Office). (1998). Morbidity and treatment of ailments, NSS 52nd Round, Report No. 441 (52/25.0/1). Ministry of Statistics and Programme Implementation, Government of India. Accessed November 14, 2014. http://mospi.nic.in/rept%20_%20pubn/441_final.pdf
NSSO (National Sample Survey Office). (2006). Morbidity, healthcare and the condition of the aged, NSS 60th Round, January–June 2004, Report No. 507 (60/25.0/1). Ministry of Statistics and Programme Implementation, Government of India. Accessed November 14, 2014. http://mospi.nic.in/rept%20_%20pubn/507_final.pdf
Panikar, P. G. K., Pillai, M. P., & Sundari, T. K. (1992). International environment multinational corporations and drug policy. Centre for Development Studies.
Pillai, P. M. (1984). Multinationals and Indian pharmaceutical industry. Kerala Sastra Sahitya Parishat.
Shivakumar, S. (2012). CRAMS in India. Cutting edge (March): 5–8. Special Correspondent, The Hindu. 2012. After Generic Medicine Supply, Rajasthan May Go for Free Diagnostic Tests. The Hindu, October 3.
United States Senate. (1961). Study of administered prices in the drug industry (Report of the Committee on the Judiciary). US Government Office.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s)
About this chapter
Cite this chapter
Dhar, B., Joseph, R.K. (2021). Developments in India’s Domestic Pharmaceutical Sector and Implications for Universal Healthcare in India. In: Qadeer, I., Saxena, K.B., Arathi, P.M. (eds) Universalising Healthcare in India. Springer, Singapore. https://doi.org/10.1007/978-981-16-5872-3_12
Download citation
DOI: https://doi.org/10.1007/978-981-16-5872-3_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-5871-6
Online ISBN: 978-981-16-5872-3
eBook Packages: Behavioral Science and PsychologyBehavioral Science and Psychology (R0)